We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Activator Protein May Be Key to Controlling Schistosomiasis

By LabMedica International staff writers
Posted on 16 Jan 2012
Parasitologists have identified a gene activator protein in Schistosoma mansoni that spurs development of the parasite after infection of its human host and is an attractive target for a new generation of drugs to control this disease.

Schistosome parasites infect more than 200 million people worldwide and cause human schistosomiasis. More...
Free-swimming schistosome larvae are highly mobile, and invade and penetrate the host's skin to perpetuate their lifecycle in their human host, growing from 90-215 µm in length as a schistosomulum to a 7-20 mm long adult worm. Few molecular pathways have been identified in schistosome worms that are important for parasite early development.

In the current study, investigators at Case Western Reserve University (Cleveland, OH, USA) focused on the gene activator protein myocyte enhancer factor 2 protein (Mef2). This protein a major regulator of muscle and nerve development in mammals and insects and is highly conserved from bread yeast to vertebrates.

They reported in the January 3, 2012, online edition of the journal PLoS Neglected Tropical Diseases that quantitative PCR demonstrated that Mef2 was expressed during several stages of schistosome development, and that it could bind to conserved Mef2 DNA consensus binding sequences. SmMef2 was shown to be a transactivator that could induce transcription of four separate heterologous reporter genes by yeast one-hybrid analysis.

The intent is to seek out drugs to target SMfe2. Although Mef2 is present in humans, the portion of SMef2 that switches on gene activity is so different from human Mef2 that it should be possible to target that part, and not affect the host.

“This is really a disease of poor people," said senior author Dr. Emmitt Jolly, professor of biology at Case Western Reserve University. “The strategy to combat the disease cannot be expensive.”

Related Links:

Case Western Reserve University



New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.